Kamada Ltd News Today

StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDA – Free Report) in a research note published on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Kamada in a report on Thursday, May 9th. View […]

StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA – Free Report) in a report published on Thursday morning. The firm issued a buy rating on the biotechnology company’s stock. Separately, HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, May 9th. Check Out […]

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and

Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...

Kamada Ltd (IL:KMDA) has released an update. Kamada Ltd., a leading biopharmaceutical company, will unveil its financial outcomes for Q1 2024 on Ma...

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....

Global Alpha-1 Antitrypsin Deficiency Industry is expected to reach US$ 10 Billion by registering a CAGR of 12.8% by 2033

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® , met its primary endpoint in patients with moderate to severe rheumatoid...